DDAVP, Stimate, Nocdurna, Noctiva
Evidence Grade A — Regulatory approved. 4171 published studies. 35 registered clinical trials.
Loading...
Desmopressin (sold as DDAVP, Stimate, Nocdurna, and other brands) is a modified version of a natural hormone that helps the body concentrate urine and retain water. Available as tablets, nasal spray, and injection, it is used for a wide range of conditions including diabetes insipidus (a condition causing excessive urination), bedwetting in children, night-time urination in adults, and certain bleeding disorders.
4,171 published studies: 3229 human, 314 animal, 147 in-vitro, 948 reviews
Desmopressin is marketed under multiple brand names including DDAVP, Stimate, Nocdurna (sublingual), and Noctiva (nasal), with the first approval around 1978. It is one of the most versatile peptide medications available, with indications spanning central diabetes insipidus, primary nocturnal enuresis (bedwetting), nocturia (night-time urination), and mild haemophilia A/von Willebrand disease.
The most important safety concern is hyponatraemia (dangerously low sodium levels) from excessive water retention, particularly in elderly patients. Fluid intake must be restricted around dosing. The sublingual formulation Nocdurna (approved 2018) for nocturia offers improved dosing precision with lower hyponatraemia risk compared to older formulations.
The two modifications to natural vasopressin give desmopressin a very specific profile: it strongly activates the kidney's water-retention receptors (V2) while having minimal effect on the blood vessel-constricting receptors (V1a). This means it concentrates urine powerfully without the dangerous blood pressure effects of vasopressin. The V2 receptor activation also triggers the release of von Willebrand factor and Factor VIII from blood vessel lining cells, which is why desmopressin helps with certain bleeding disorders like mild haemophilia A and von Willebrand disease.
Desmopressin has been a standard treatment for central diabetes insipidus for over 40 years and is also uniquely valuable for mild haemophilia A and von Willebrand disease, where it can boost the body's own clotting factors enough to avoid the need for blood-derived products during minor procedures. Newer formulations have expanded its use: Nocdurna (a sublingual tablet) was approved in 2018 for adults bothered by waking frequently to urinate at night, with sex-specific dosing designed to reduce the main safety risk. That main risk is dangerously low sodium levels (hyponatraemia) caused by excessive water retention, particularly in elderly patients. Fluid restriction around dosing is essential. An earlier intranasal formulation for childhood bedwetting was withdrawn in 2007 after cases of severe hyponatraemia in children. The market is now largely generic, with limited ongoing research.
DDAVP Effect by TEG6 in Cardiac Surgery
Transfusion Reduction in High-Bleeding-Risk Cardiac Surgery With Desmopressin
Effectiveness of Pelvic Floor Muscle Rehabilitation Combined With Desmopressin in Children With Primary Monosymptomatic Nocturnal Enuresis
Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD
Intravenous Tranexamic Acid and Intramyometrial Desmopressin Effect on Blood Loss During Laparoscopic Myomectomy.
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 2
FDA SUPPL 5
FDA SUPPL 8
FDA SUPPL 9
FDA SUPPL 10
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 13
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 2
FDA SUPPL 4
FDA SUPPL 2
Health Canada Market Authorisation
FDA SUPPL 3
FDA SUPPL 17
FDA SUPPL 5
FDA SUPPL 19
FDA SUPPL 8
FDA SUPPL 10
FDA SUPPL 23
FDA ORIG 1
FDA SUPPL 13
FDA SUPPL 27
FDA SUPPL 13
FDA SUPPL 5
FDA ORIG 1
FDA SUPPL 16
FDA SUPPL 17
FDA SUPPL 8
FDA SUPPL 15
FDA ORIG 1
FDA SUPPL 29
FDA ORIG 1
FDA ORIG 1
FDA SUPPL 35
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 1
FDA SUPPL 22
FDA SUPPL 23
FDA SUPPL 39
FDA ORIG 1
FDA SUPPL 20
FDA SUPPL 8
FDA SUPPL 8
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg. The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide. Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy. Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
